New Gene Mutation Associated with Fanconi Anemia
By LabMedica International staff writers Posted on 25 Jul 2017 |
Image: The enzyme E3 ubiquitin ligase (RFWD3) helps target other proteins on single-stranded DNA for degradation. B: Cells lacking RFWD3 show DNA repair defects (Photo courtesy of Julius-Maximilians-Universität).
Fanconi anemia is a rare genetic disease characterized by bone marrow failure heralded by low platelet counts and unusually large red blood cells. Mutations in over 20 genes have been identified as causative for Fanconi anemia, which encode proteins commonly involved in DNA repair mechanisms.
Safeguarding of the genome is essential for the suppression of oncogenesis and for stem cell maintenance in many organisms, and is warranted by DNA repair mechanisms. If they fail on a genetic basis, DNA repair disorders occur and Fanconi anemia (FA) is such a rare human genomic instability disease.
Scientists at the Julius-Maximilians-Universität (Würzburg, Germany) reports classical Fanconi anemia symptoms in a 12-year-old individual without mutations in any of the known Fanconi anemia genes. The patient presented with congenital abnormalities characteristic of FA and had a typical FA phenotype and compound heterozygous mutations in the E3 ubiquitin ligase (RFWD3).
The team used various techniques in the study including DNA sample preparation, polymerase chain reaction (PCR), Sanger sequencing, and whole exome sequencing, on a HighSeq2000 instrument. Other methods used were generation of stable lentiviral producer lines and transduction of adherent cells, DT40 gene targeting, cell cycle, cell survival, and chromosomal studies, where cell numbers were determined using a Nucleo Counter NC-250. Immunofluorescence studies were analyzed on a BIOREVO BZ-9000 microscope.
Sequencing of this individual's genome detected mutations in both alleles of the gene RFWD3, which encodes an enzyme that helps target other proteins on single-stranded DNA for degradation. This process is impaired in patient's cells, which rendered them more sensitive to chromosome breakage and DNA damage, compared to cells from healthy individuals. Other cells either lacking RFWD3 or genetically engineered with the patient's missense mutation showed similar DNA repair defects, which were rescued by expression of wild-type RFWD3. Together, these findings support the identification of RFWD3 as a Fanconi anemia gene. The study was published on July 10, 2017, in the Journal of Clinical Investigation.
Related Links:
Julius-Maximilians-Universität
Safeguarding of the genome is essential for the suppression of oncogenesis and for stem cell maintenance in many organisms, and is warranted by DNA repair mechanisms. If they fail on a genetic basis, DNA repair disorders occur and Fanconi anemia (FA) is such a rare human genomic instability disease.
Scientists at the Julius-Maximilians-Universität (Würzburg, Germany) reports classical Fanconi anemia symptoms in a 12-year-old individual without mutations in any of the known Fanconi anemia genes. The patient presented with congenital abnormalities characteristic of FA and had a typical FA phenotype and compound heterozygous mutations in the E3 ubiquitin ligase (RFWD3).
The team used various techniques in the study including DNA sample preparation, polymerase chain reaction (PCR), Sanger sequencing, and whole exome sequencing, on a HighSeq2000 instrument. Other methods used were generation of stable lentiviral producer lines and transduction of adherent cells, DT40 gene targeting, cell cycle, cell survival, and chromosomal studies, where cell numbers were determined using a Nucleo Counter NC-250. Immunofluorescence studies were analyzed on a BIOREVO BZ-9000 microscope.
Sequencing of this individual's genome detected mutations in both alleles of the gene RFWD3, which encodes an enzyme that helps target other proteins on single-stranded DNA for degradation. This process is impaired in patient's cells, which rendered them more sensitive to chromosome breakage and DNA damage, compared to cells from healthy individuals. Other cells either lacking RFWD3 or genetically engineered with the patient's missense mutation showed similar DNA repair defects, which were rescued by expression of wild-type RFWD3. Together, these findings support the identification of RFWD3 as a Fanconi anemia gene. The study was published on July 10, 2017, in the Journal of Clinical Investigation.
Related Links:
Julius-Maximilians-Universität
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans